PFA Pension Forsikringsaktieselskab Takes $46.83 Million Position in Edwards Lifesciences Corporation $EW

PFA Pension Forsikringsaktieselskab bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 543,261 shares of the medical research company’s stock, valued at approximately $46,829,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $25,000. True Wealth Design LLC lifted its holdings in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 259 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at $28,000. Hantz Financial Services Inc. lifted its holdings in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 164 shares in the last quarter. Finally, Dorato Capital Management acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at $29,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent research reports. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Barclays restated an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Evercore restated an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a report on Friday, April 24th. Wells Fargo & Company lifted their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Finally, TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $95.65.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $84.08 on Friday. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The firm has a market capitalization of $48.47 billion, a P/E ratio of 44.72, a P/E/G ratio of 2.11 and a beta of 0.87. The company’s fifty day moving average price is $82.08 and its two-hundred day moving average price is $82.47.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.17%. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the previous year, the business posted $0.64 EPS. The firm’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the completion of the sale, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. This trade represents a 53.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 86,058 shares of company stock worth $7,118,636 in the last quarter. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.